Loading…
Lexaria Bioscience Corp. is projected to rise to $5.50 by 2027, a +16% move from its current price of $4.75. LEXX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $4.35 | $4.75 | $5.18 | -0.07% |
| Aug 6 | $4.19 | $4.74 | $5.36 | -0.15% |
| Aug 7 | $4.08 | $4.74 | $5.51 | -0.22% |
| Aug 8 | $3.98 | $4.74 | $5.64 | -0.29% |
| Aug 9 | $3.90 | $4.73 | $5.75 | -0.36% |
| Aug 10 | $3.82 | $4.73 | $5.85 | -0.44% |
| Aug 11 | $3.76 | $4.73 | $5.95 | -0.51% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.76 | $4.73 | $5.95 | -0.51% |
| Week 2 | $3.40 | $4.70 | $6.51 | -1.01% |
| Week 3 | $3.14 | $4.68 | $6.97 | -1.51% |
| Week 4 | $2.94 | $4.65 | $7.37 | -2.01% |
| Week 5 | $2.77 | $4.63 | $7.74 | -2.51% |
| Week 6 | $2.62 | $4.61 | $8.09 | -3.01% |
| Week 7 | $2.49 | $4.58 | $8.42 | -3.50% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lexaria Bioscience Corp. is a healthcare-focused biotechnology company. It offers the DehydraTECH platform, a patented drug delivery-enabling technology that combines active pharmaceutical ingredients with specific long-chain fatty acid-rich triglyceride oils and carrier compounds to improve how they enter the bloodstream, increasing effectiveness while allowing for lower overall dosing and healthier oral ingestion methods.
The DehydraTECH platform is applied to a range of active molecules, including GLP-1 drugs and GIP, vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, nicotine and its analogs, and cannabinoids. It covers a variety of therapeutic indications and product formats, including oral suspensions, tablets, capsules, foods, beverages, and oral products, suitable for pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods.
Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada. It was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016.
Lexaria Bioscience Corp. (LEXX) operates in the Healthcare sector, with a current price of $0.3963. Its market capitalization is $9.82M and it is ranked 4811 by market size.
The provided forecast outlines the asset’s price path, starting with a near-term flat stance in 2026 (min $0.396, avg $0.3963, max $0.4374; ROI 0; sentiment NEUTRAL) and moving into a bullish trajectory in later years, culminating in higher price levels and positive returns through 2030 and beyond.
In the longer term, the forecast shows progressively higher average prices and notable upside, including a max of $0.955 in 2030 and a max of $3.56 by 2050, reflecting a bullish long-term outlook with rising momentum.
A major floor 91.7% below — a decisive break under it would weaken the trend.
The nearest floor, 88.8% below — buyers have tended to step in here.
The nearest ceiling, 23.5% above — a clean break opens room to run.
A major ceiling 100.2% above — clearing it would confirm fresh momentum.
Key LEXX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LEXX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.57 | Buy | $2.28 | Buy |
| MA 10 | $1.07 | Buy | $1.50 | Buy |
| MA 20 | $0.8314 | Buy | $1.06 | Buy |
| MA 50 | $0.6937 | Buy | $0.8043 | Buy |
| MA 100 | $0.7434 | Buy | $0.7634 | Buy |
| MA 200 | $0.7972 | Buy | $0.8385 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 94.94 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 666.67 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.33 | Buy |
| ROC (12) | 897.45 | Buy |
| Bollinger %B (20,2) | 1.59 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 1.41 | Buy |
| Awesome (5,34) | 0.85 | Buy |
| Ultimate (7,14,28) | 95.42 | Sell |
| Momentum (10) | 5.22 | Buy |
| Aroon Osc (25) | 4.00 | Buy |
| Hull MA (9) | 2.07 | Buy |
| ADX (14) | 19.19 | Neutral |
| ATR (14) | 0.42 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 30.
Near-term momentum is tempered by a relatively low RSI, while the trend is influenced by near-term price levels shown by the SMA indicators. The SMA50 is $0.5877 and the SMA200 is $0.7723, indicating the current price sits below both moving averages.
Support is listed at $0.396 and resistance at $0.647. The 30-day price range spans $0.2718 to $0.5779, highlighting limited upside in the very near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.53 | $4.75 | $5.42 | 0% | Neutral | |
| $4.01 | $5.50 | $8.16 | +16% | Neutral | |
| $4.66 | $6.80 | $10.76 | +43% | Bullish | |
| $4.88 | $7.50 | $12.47 | +58% | Bullish | |
| $4.62 | $7.45 | $12.90 | +57% | Bullish | |
| $4.52 | $7.62 | $13.67 | +61% | Bullish | |
| $4.13 | $7.26 | $13.42 | +53% | Bullish | |
| $3.47 | $6.36 | $12.08 | +34% | Bullish | |
| $4.40 | $8.39 | $16.35 | +77% | Bullish | |
| $5.52 | $10.94 | $21.82 | +130% | Bullish | |
| $5.43 | $12.07 | $26.46 | +154% | Bullish | |
| $12.43 | $27.63 | $63.56 | +482% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.53 | $4.75 | $5.42 | +0.00% |
| September 2026 | $3.47 | $4.22 | $5.35 | -11.14% |
| October 2026 | $3.61 | $4.45 | $5.75 | +5.32% |
| November 2026 | $3.49 | $4.35 | $5.72 | -2.18% |
| December 2026 | $3.22 | $4.06 | $5.42 | -6.64% |
Click any year to see its month-by-month LEXX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, LEXX is projected to trade between $0.53 and $5.42, averaging $4.75 — a potential gain of 0% from today's $4.75. Price action looks broadly range-bound.
Lexaria Bioscience Corp.'s 2027 outlook centres on $5.50, within a $4.01 to $8.16 range. That is up +16% on the projected 2026 average. That marks a +16% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, LEXX could reach as high as $10.76, with a base case around $6.80 and support toward $4.66 — roughly +43% from $4.75. Momentum favours further upside here.
Expect LEXX to range from $4.88 to $12.47 through 2029. The $7.50 average target implies a +58% move from current prices. That is up +10% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The LEXX price prediction for 2030 points to an average of $7.45 (low $4.62, high $12.90) — a potential gain of +57% on today's $4.75. Momentum favours further upside here.
In 2031, LEXX is projected to trade between $4.52 and $13.67, averaging $7.62 — a potential gain of +61% from today's $4.75. That is up +2% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Lexaria Bioscience Corp.'s 2032 outlook centres on $7.26, within a $4.13 to $13.42 range. That is -5% versus the projected 2031 average. That marks a +53% change versus current levels. Momentum favours further upside here.
By 2033, LEXX could reach as high as $12.08, with a base case around $6.36 and support toward $3.47 — roughly +34% from $4.75. Buyers look set to stay in control over this stretch.
Expect LEXX to range from $4.40 to $16.35 through 2034. The $8.39 average target implies a +77% move from current prices. That is up +32% on the projected 2033 average. Momentum favours further upside here.
The LEXX price prediction for 2035 points to an average of $10.94 (low $5.52, high $21.82) — a potential gain of +130% on today's $4.75. Buyers look set to stay in control over this stretch.
In 2040, LEXX is projected to trade between $5.43 and $26.46, averaging $12.07 — a potential gain of +154% from today's $4.75. That is up +10% on the projected 2035 average. Momentum favours further upside here.
Lexaria Bioscience Corp.'s 2050 outlook centres on $27.63, within a $12.43 to $63.56 range. That is up +129% on the projected 2040 average. That marks a +482% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in LEXX today (≈ 210.526316 LEXX) could be worth
$5,817.5
+$4,817.5 (+482%) by 2050 · US Dollar
Based on the average projected LEXX price of $27.63 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LEXXwould be worth at today's price.
$1,000 invested in LEXX on Jul 31, 2025 (≈ 1,111.111141 LEXX) would be worth
$5,277.78
+$4,277.78 (+427.8%) today · 5.28× · US Dollar
Based on a LEXX entry price of $0.9 vs. today's $4.75.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.559 | $8,497.32 | +749.7% |
| 1 month ago | $0.572 | $8,304.2 | +730.4% |
| 3 months ago | $0.711 | $6,680.73 | +568.1% |
| 6 months ago | $0.792 | $5,997.47 | +499.7% |
| 1 year ago | $0.9 | $5,277.78 | +427.8% |
| All time (5.0y) ago | $6.09 | $779.97 | -22.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LEXX forecast.
Our base-case forecast reaches $9.50 around 2035.
Implied market cap at $9.50: $15.7M
The multi-year forecast shows a gradual uptrend with several bullish years and positive returns. In 2029 the avg price is $0.5302 with a max of $0.8818 and ROI of 33.8, followed by a stronger 2030 where the avg is $0.5514, the max is $0.955, and ROI is 39.1, with sentiment BULLISH.
2031 and 2032 continue the bullish tone, with avg prices of $0.549 and $0.5164 and max prices of $0.9846 and $0.9552, yielding ROIs of 38.5 and 30.3 respectively. The 2035 forecast shows a meaningful rise, with an avg of $0.6184 and a max of $1.23 (ROI 56) and bullish sentiment.
The forecast projects substantial upside in 2040 (avg $0.7492, max $1.64; ROI 89) and an extraordinary potential by 2050 (avg $1.55, max $3.56; ROI 290.6) with bullish sentiment. Overall, these figures imply a long-run appreciation path, but they are estimates and not guaranteed, with risk in early years such as 2027 when near-term returns dip.
Tap a question to reveal the answer.
The 2030 forecast shows a min of $0.3417, an avg of $0.5514, and a max of $0.955, with a forecast ROI of 39.1 and a BULLISH sentiment.
Near term is mixed, with 2026 avg $0.3963 and ROI 0 (neutral) and 2027 avg $0.3851 with ROI -2.8 (neutral). Longer term shows bullish potential, with higher averages and bulls through 2050 (for example 2029 avg $0.5302, 2030 avg $0.5514, and 2050 max $3.56; ROI up to 290.6).
Yes. The forecast includes a 2035 max price of $1.23 and a 2040 max of $1.64, indicating a path to exceed $1 by the mid-2030s and beyond.
Current price is $0.3963 and market cap is $9.82M.
The strongest gains appear toward the end of the forecast horizon, with a 2050 max price of $3.56 and a forecast ROI of 290.6, reflecting a long-term bullish path.
Lexaria Bioscience Corp. Community Discussion
0Share your Lexaria Bioscience Corp. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.